NEWS HIGHLIGHTS
Published Studies Related to Nystatin Vaginal
Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. [2007.09]
OBJECTIVE: Fungal peritonitis (FP) is a serious complication of continuous ambulatory peritoneal dialysis (CAPD), being associated with significant morbidity and mortality. The role of nystatin prophylaxis during antibiotic therapy in the prevention of FP remains controversial, especially in programs with a modest or low baseline FP rate. The aim of the present study was to evaluate the effect of nystatin prophylaxis on the occurrence of FP in programs with a relatively modest baseline FP rate... CONCLUSION: Oral nystatin prophylaxis might prevent the occurrence of AR-FP in CAPD patients, resulting in a trend toward reduction in the incidence of FP even in programs with a modest baseline FP rate. A large scale, prospective, randomized controlled trial is needed to further examine this issue.
Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. [2004.12]
OBJECTIVE: We compared metronidazole 0.75% gel (containing 37.5 mg metronidazole per dose) with ovules containing metronidazole 500 mg and nystatin 100,000 U, for intravaginal treatment of bacterial vaginosis (BV)... CONCLUSION: Metronidazole/nystatin ovules were significantly more effective than metronidazole gel. Unprotected sex predicted recurrence after initial improvement.
A comparative clinical evaluation of econazole nitrate, miconazole, and nystatin in the treatment of vaginal candidiasis. [2000.01]
A controlled triple open clinical study on three vaginal tablets--Econazole nitrate, Miconazole and Nystatin, was carried out. Seventy-five patients, aged between 18 and 45 years, presenting with mycologically proven cases of vaginal candidiasis, met certain set criteria and were admitted into the study.
A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. [1990.12.20]
BACKGROUND.Consequently, the empirical recommendation of long-term nystatin therapy for such women appears to be unwarranted.
Clinical Trials Related to Nystatin Vaginal
A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis [Completed]
In resource constrained societies and where HIV is a problem, oral thrush causes significant
morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are
relatively expensive compared to GV solution and ketoconazole has significant side effects
especially in association with some of the treatments for HIV related problems.
In children, either GV solutions or nystatin are used, GV is a fraction of the cost of
nystatin.
GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark
them out as having HIV infections. A much more dilute solution of GV has proved equally
effective in vitro and would not carry the same cosmetic problem.
In this study of children, the investigators have compared the 3 solutions, 1% GV, 0. 00165%
GV and nystatin oral drops - all masked so that they look the same - to see if GV is more
effective than nystatin, and to see if the weaker solution of GV is as effective as the
stronger solution.
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection. [Completed]
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous
nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and
clinical pharmacology of intravenous nystatin.
A Study of Nystatin in HIV-Infected Patients [Completed]
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous
nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the
safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI)
administered in an alternating regimen in this patient population.
Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC [Completed]
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the
prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group III
or IV, CDC classification).
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes [Completed]
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the
prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or
IV, CDC classification)
|
